小型脉络膜黑色素瘤:生长速度与病理学的相关性。

IF 0.9 Q4 OPHTHALMOLOGY Ocular Oncology and Pathology Pub Date : 2021-12-01 Epub Date: 2021-07-30 DOI:10.1159/000517203
Vishal Raval, Shiming Luo, Emily C Zabor, Arun D Singh
{"title":"小型脉络膜黑色素瘤:生长速度与病理学的相关性。","authors":"Vishal Raval, Shiming Luo, Emily C Zabor, Arun D Singh","doi":"10.1159/000517203","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The aim of the study was to evaluate equivalence of growth rate and pathologic confirmation in small choroidal melanoma (SCM).</p><p><strong>Design: </strong>This study is a case series.</p><p><strong>Subjects participants and controls: </strong>A total of 61 patients with a choroidal melanocytic tumor of size 5.0-16.0 mm in the largest basal diameter and 1.0-2.5 mm in thickness were classified into the pathology-confirmed group (<i>n</i> = 19), growth-confirmed group (<i>n</i> = 30), and with combined observations (<i>n</i> = 12).</p><p><strong>Methods: </strong>Distribution of clinical variables (age, gender, laterality, tumor dimensions, tumor location, and presence of orange pigment, subretinal fluid, drusen, and retinal pigment epithelial [RPE] atrophy) between the groups was analyzed. Patient and disease characteristics were summarized as the median and interquartile range for continuous variables and the frequency and percentage for categorical variables. Comparisons were made using the Wilcoxon rank sum test for continuous variables and either Fisher's exact test or the χ<sup>2</sup> test for categorical variables with a <i>p</i> value threshold of 0.05 for statistical significance. Growth rate (change in basal dimension/12 months) diagnostic of SCM was quantified.</p><p><strong>Main outcome measures: </strong>The primary aim of this study was to test the hypothesis that \"growth\" was diagnostic of SCM with the secondary aim of quantifying the malignant \"growth rate\" (growth rate of SCM).</p><p><strong>Results: </strong>The clinical characteristics among all 3 groups were similar except more patients with symptoms (68 vs. 20 vs. 42%, <i>p</i> = 0.004) and juxtapapillary location (<i>p</i> = 0.03) were in the pathology group than in the growth-confirmed group. Those in the combined and growth-confirmed groups had more patients with drusen (11 vs. 60 vs. 50%, <i>p</i> = 0.003) and RPE atrophy (11 vs. 23 vs. 67%, <i>p</i> = 0.003), respectively, than in the pathology group. The median time to detect growth was 9 months (range 3-26 months). The mean growth rate in basal dimension was 1.8 mm/12 months (range, 0.0-7.4 mm; [95% CI: 1.32-2.28]).</p><p><strong>Conclusions and relevance: </strong>Choroidal melanocytic lesions exhibiting a defined growth rate can be clinically diagnosed as SCM without a need for biopsy.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740066/pdf/oop-0007-0401.pdf","citationCount":"0","resultStr":"{\"title\":\"Small Choroidal Melanoma: Correlation of Growth Rate with Pathology.\",\"authors\":\"Vishal Raval, Shiming Luo, Emily C Zabor, Arun D Singh\",\"doi\":\"10.1159/000517203\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The aim of the study was to evaluate equivalence of growth rate and pathologic confirmation in small choroidal melanoma (SCM).</p><p><strong>Design: </strong>This study is a case series.</p><p><strong>Subjects participants and controls: </strong>A total of 61 patients with a choroidal melanocytic tumor of size 5.0-16.0 mm in the largest basal diameter and 1.0-2.5 mm in thickness were classified into the pathology-confirmed group (<i>n</i> = 19), growth-confirmed group (<i>n</i> = 30), and with combined observations (<i>n</i> = 12).</p><p><strong>Methods: </strong>Distribution of clinical variables (age, gender, laterality, tumor dimensions, tumor location, and presence of orange pigment, subretinal fluid, drusen, and retinal pigment epithelial [RPE] atrophy) between the groups was analyzed. Patient and disease characteristics were summarized as the median and interquartile range for continuous variables and the frequency and percentage for categorical variables. Comparisons were made using the Wilcoxon rank sum test for continuous variables and either Fisher's exact test or the χ<sup>2</sup> test for categorical variables with a <i>p</i> value threshold of 0.05 for statistical significance. Growth rate (change in basal dimension/12 months) diagnostic of SCM was quantified.</p><p><strong>Main outcome measures: </strong>The primary aim of this study was to test the hypothesis that \\\"growth\\\" was diagnostic of SCM with the secondary aim of quantifying the malignant \\\"growth rate\\\" (growth rate of SCM).</p><p><strong>Results: </strong>The clinical characteristics among all 3 groups were similar except more patients with symptoms (68 vs. 20 vs. 42%, <i>p</i> = 0.004) and juxtapapillary location (<i>p</i> = 0.03) were in the pathology group than in the growth-confirmed group. Those in the combined and growth-confirmed groups had more patients with drusen (11 vs. 60 vs. 50%, <i>p</i> = 0.003) and RPE atrophy (11 vs. 23 vs. 67%, <i>p</i> = 0.003), respectively, than in the pathology group. The median time to detect growth was 9 months (range 3-26 months). The mean growth rate in basal dimension was 1.8 mm/12 months (range, 0.0-7.4 mm; [95% CI: 1.32-2.28]).</p><p><strong>Conclusions and relevance: </strong>Choroidal melanocytic lesions exhibiting a defined growth rate can be clinically diagnosed as SCM without a need for biopsy.</p>\",\"PeriodicalId\":19434,\"journal\":{\"name\":\"Ocular Oncology and Pathology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740066/pdf/oop-0007-0401.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ocular Oncology and Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000517203\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/7/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Oncology and Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000517203","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在评估小脉络膜黑色素瘤(SCM)的生长速度和病理确认的等效性:本研究为病例系列研究:共61例脉络膜黑色素细胞瘤患者,最大基底直径5.0-16.0毫米,厚度1.0-2.5毫米,分为病理证实组(19例)、生长证实组(30例)和综合观察组(12例):方法:分析各组之间的临床变量(年龄、性别、侧位、肿瘤尺寸、肿瘤位置以及是否存在橙色色素、视网膜下积液、色素沉着和视网膜色素上皮[RPE]萎缩)的分布情况。患者和疾病特征的连续变量以中位数和四分位数间距表示,分类变量以频率和百分比表示。连续变量的比较采用 Wilcoxon 秩和检验,分类变量的比较采用 Fisher's exact 检验或 χ2 检验,统计学意义的 p 值阈值为 0.05。主要结果测量指标:本研究的主要目的是检验 "生长 "是否可诊断为单核细胞增多症的假设,其次是量化恶性 "生长率"(单核细胞增多症的生长率):三组患者的临床特征相似,但病理组中有症状(68 vs. 20 vs. 42%, p = 0.004)和并乳头位置(p = 0.03)的患者多于生长证实组。与病理组相比,合并组和生长确诊组中分别有更多的患者伴有葡萄肿(11 对 60 对 50%,p = 0.003)和 RPE 萎缩(11 对 23 对 67%,p = 0.003)。检测到生长的中位时间为 9 个月(3-26 个月)。基底维度的平均增长率为 1.8 毫米/12 个月(范围为 0.0-7.4 毫米;[95% CI:1.32-2.28]):脉络膜黑色素细胞病变具有明确的生长速度,无需活检即可临床诊断为单核细胞增多症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Small Choroidal Melanoma: Correlation of Growth Rate with Pathology.

Purpose: The aim of the study was to evaluate equivalence of growth rate and pathologic confirmation in small choroidal melanoma (SCM).

Design: This study is a case series.

Subjects participants and controls: A total of 61 patients with a choroidal melanocytic tumor of size 5.0-16.0 mm in the largest basal diameter and 1.0-2.5 mm in thickness were classified into the pathology-confirmed group (n = 19), growth-confirmed group (n = 30), and with combined observations (n = 12).

Methods: Distribution of clinical variables (age, gender, laterality, tumor dimensions, tumor location, and presence of orange pigment, subretinal fluid, drusen, and retinal pigment epithelial [RPE] atrophy) between the groups was analyzed. Patient and disease characteristics were summarized as the median and interquartile range for continuous variables and the frequency and percentage for categorical variables. Comparisons were made using the Wilcoxon rank sum test for continuous variables and either Fisher's exact test or the χ2 test for categorical variables with a p value threshold of 0.05 for statistical significance. Growth rate (change in basal dimension/12 months) diagnostic of SCM was quantified.

Main outcome measures: The primary aim of this study was to test the hypothesis that "growth" was diagnostic of SCM with the secondary aim of quantifying the malignant "growth rate" (growth rate of SCM).

Results: The clinical characteristics among all 3 groups were similar except more patients with symptoms (68 vs. 20 vs. 42%, p = 0.004) and juxtapapillary location (p = 0.03) were in the pathology group than in the growth-confirmed group. Those in the combined and growth-confirmed groups had more patients with drusen (11 vs. 60 vs. 50%, p = 0.003) and RPE atrophy (11 vs. 23 vs. 67%, p = 0.003), respectively, than in the pathology group. The median time to detect growth was 9 months (range 3-26 months). The mean growth rate in basal dimension was 1.8 mm/12 months (range, 0.0-7.4 mm; [95% CI: 1.32-2.28]).

Conclusions and relevance: Choroidal melanocytic lesions exhibiting a defined growth rate can be clinically diagnosed as SCM without a need for biopsy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
20
期刊最新文献
Description and Characteristics of Ocular Tumor Lysis Syndrome. How Much Time Do Focal Treatments for Retinoblastoma Add to Anesthetic Exposure? Ruthenium-106 Plaque Brachytherapy for Circumscribed Choroidal Hemangioma: A Case Series and Review of Literature. Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature. Clinicopathologic Features of Eyelid Sebaceous Gland Carcinoma Requiring Immunohistochemical Diagnosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1